Deliver logo
Program Overview
Extracellular Vesicles and Advanced Therapies ( Shanghai ) Summit 2023 will bring in fresh perspectives and establish an efficient platform for Academia & Industry to discuss about the Current and Future Perspectives of Exosomes; Extracellular Vesicles; Drug Delivery Platform; Advanced Cell and Gene Therapies Revolution.

Brainstorm with over 100+ high caliber speakers and estimation to bring over 500+ Industry Stakeholders, Entrepreneurs, Exosomes and Extracellular Vesicles Principal Investigators, Cell and Gene Therapy Pioneers, Influencers and Pharma R&D professionals. With this in mind, The Themes of " Extracellular Vesicles and Advanced Therapies ( Shanghai ) Summit 2023 " will cover

Exosomes and Extracellular Vesicles:
* Exosomes Biology, Function and Emerging Therapeutic Opportunities -- From Academia Innovation to Industry Translation
-- The Biology and Function of Exosomes in Cancer and Potential Therapeutic Strategy
-- Extracellular Vesicles; Biology and Emerging Therapeutic Opportunities and DeliverEX Platform
-- Development of Engineered Exosome Therapeutics and Codiak’s proprietary engEx Platform
-- Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine
-- Extracellular Vesicles Derived from Chimeric Antigen Receptor-T Cells: A Potential Therapy for Cancer
-- Mesenchymal stem cell (MSC)-derived Exosome for Clinical Use

* Exosomes, Extracellular Vesicles - Clinical Research and Implications, Biologic Function, Therapeutic Potential
-- The Latest Clinical Research Progress in the Application of Exosomes in Cancer Immuno-editing and Immunotherapy
-- Extracellular Vesicles Research Technologies Innovation and Industry Translation
-- Exosomes/EV-based Therapeutics Development and Clinical Research
-- Exosomes/EVs Derived from Adult Stem Cells and Their Therapeutics / Functional Activities / Regenerative Properties
-- Novel Biosensing and Imaging Technologies for Analysis of Extracellular Vesicles
-- Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3
-- Exosome Surface Functionalization and its Applications in Diagnosis and Therapy

* Quality Control , CMC, Clinical Grade Exosome GMP Manufacturing; GMP Manufacturing Therapeutic Exosomes
-- Quality Control in the Use of Exosomes/EVs for Therapeutics
-- Considerations on Regulatory CMC Dossier Preparation of EV- Based Therapeutics
-- GMP Manufacturing Therapeutic Exosomes: from Bench to Industry
-- Technologies for Isolation and Characterization as Well as High-Volume Production of EVs for Potential Therapeutics Applications

* Exosomes for mRNA Delivery and Exosomal CircRNAs
-- Exosomes for mRNA Delivery -- A Novel Bio-therapeutic Strategy Development Opportunities in China and Challenges
-- Therapeutics Potential and Technology Advances in the EV Field as well as mRNA Drug Delivery and Therapeutics Development
-- Extracellular Vesicle-mediated Delivery of circDYM Alleviates CUS-induced Depressive-like Behaviors ( RVG-circDYM-EVs )
-- The Molecular Mechanisms of circRNAs and Recent Findings regarding Exosomal CircRNAs, Highlight the Specific Roles of Exosomal circRNAs in Human Cancer
-- Corilagin inhibits SARS-CoV-2 replication bytargeting viral RNA-dependent RNA polymerase / Topic in the field of IncRNAs

Circular RNAs and mRNA-Based Therapeutics Development, mRNA Production and Process Development:
* mRNA-Based Therapeutics Development, mRNA Production and Process Development
-- Developing Raw Materials for mRNA Vaccines and Collaboration Opportunities
-- The Future of mRNA-Based Therapeutics for Infectious Diseases
-- The Future mRNA-Based Therapeutics and Vaccines for Cancer Immunotherapy
-- LPP/mRNA Vaccine Products Development in China
-- Development of messenger RNA (mRNA) therapeutics by lipid nanoparticles (LNP): The Latest Advancement & Collaboration Opportunities
-- VLP-mRNA Delivery Technology and VLP-mRNA Vaccine Products Development
-- Innovation in China -- Strengthening collaboration to Embrace mRNA-Based COVID-19 Vaccine Development in China
-- mRNA production and process development, Manufacturing of mRNA-based Therapeutics
-- Messenger RNA (mRNA)-based therapeutics Revolution - Regulatory, Development & Commercialization Considerations of mRNA-based Therapies in China

* Circular RNAs: New Mechanisms and Applications
-- Translation of circular RNAs: new mechanisms and applications

-- Circular RNAs: novel circularization strategy, vaccine and RiboPROTAC
-- Circular RNA: Platform and Applications
-- Beyond CRISPR: RNA Base Editing Mediated by Endogenous ADAR, A Novel Approach for in vivo Gene Editing Therapy

Gene Therapy Bioprocessing, Manufacturing, Viral Vector Manufacturing and Plasmid Production:
* Gene Therapy Development & CMC Challenges; Process Development & Plasmid Production
-- Gene Therapy AAV Vector Process Development Strategies for Clinical Material Manufacturing
-- Gene Therapy Viral Vector Production and Process Development Scale-up Strategies
-- Analysis of Key Elements in Large Scale GMP Grade AAV Manufacturing
-- AAV-based Gene Therapeutics a Complex Manufacturing Process
-- The CMC Challenges in AAV Gene Therapy Development
-- The CMC and Clinical Outcomes Considerations towards Development of In Vivo Gene Therapies
-- Gene Therapies Viral Vector Manufacturing; Plasmid Production and Collaboration Considerations

NK Cell-based Therapies and iPSC Therapies:
* Manufacturing iPSC Therapies; Developing hESC/iPSC-Derived NK Cell Therapeutics
-- Manufacturing iPSC Therapies -- Manufacturing of Next-Generation Cellular Immunotherapies using a Novel Induced Pluripotent Stem Cell Platform
-- Technological Progress in Generation, Maintenance, Engineering and Differentiation of Pluripotent Stem Cells
-- Development of the Next Generation Cell Therapy via iPSC-CAR-NK
-- Gene modified NK cells: From Natural Basis to Design for Adaptation and Kill
-- Development First-in-Class CAR iNKs and iPSC-derived CAR-NKs in Heme and Solid Tumors
-- Drug Development Experience of the First hESC-derived Cell Drug in China
-- Development Universal iPSC-CAB-NK Cell Therapy Products targeting Solid Tumor
-- Development Next Generation iPSC-Derived Cell Therapy Products

* Engineering the Next Generation of CAR-NK immunotherapies: Products Development, Manufacturing Process & Quality Control
-- The "Super NK" cells, genetically engineered with enhanced NK function, demonstrating superior killing capacity against blood and solid tumor
-- The Essential Technology Roadmap of a Successful NK/CAR-NK Immune Therapy Products
-- NK Cell-based Therapies are Emerging as Safe and Efficacious Treatments for NHL
-- Engineering Next Generation Super-NK Cell Therapies
-- NK Cell Expansion Scale Up for Adoptive Immunotherapy
-- Manufacturing & Clinical Study of CAR-NK Cell Drugs to Treat Solid Tumors
-- Developing and manufacturing universal "off-the-shelf" Memory NK and CAR-T cells for the treatment of solid tumors, T-cell malignancies, Acute Myeloid Leukemia, and Multiple Myeloma
-- Strengthening Global Collaboration for Development Next Generation Off-the-Shelf, CAR-NK Cell Therapy Products - Opportunities and Challenges

Current Status and Future Directions of Cellular Cancer Immunotherapy Development
* Universal Cell Therapy Products Development – The Latest Advancement and Challenges
-- The Latest Development and Progress of Universal CAR-T (UCAR-T) Cell Therapy
-- Development of Next Generation UCAR-T for Cancer
-- Advanced Gene Editing in the Development of Next Generation of CAR-T Therapies
-- Technology and Clinical Trial Study of Universal CAR-T Cells for Solid Tumors
-- Research and Development of CD7-UCAR-T Cell Therapy

* The State of the ART of Cell Therapy Products Development and Collaboration Opportunities
-- Cell Based Therapies: Key Considerations for Clinicians, Health Care Systems, International Societies and Regulatory Authorities
-- A Fresh Look at CAR T-Cell Therapy: Recent Advances, New Evidence, and Evolving Paradigms to Improve Patient Care
-- Precision Immunotherapy - Clinical Development of Next-Generation CAR T Cell Therapies: Challenges and Collaboration Opportunities
-- Combining CAR-T Cell Therapy with Clinical Needs: Key Considerations
-- Opening a New Era of Cell Therapy in China – The State of the ART of Cell Therapy Products Development in China
-- Clinical Development of CAR T Cell Therapy in China: The Latest Progress and Collaboration Opportunities
EVs and Advanced Therapies Summit 2023  |  Telephone: +86 21 6157 7321  |  E-mail: kevin.tan@deliver-consulting.com
© Extracellular Vesicles and Advanced Therapies Summit 2023- All rights reserved